Anavex Life Sciences Corp.: updates and filings

AVXLNASDAQHealthcare · Biological Products, (No Diagnostic Substances)

Price

$0.59

November 20, 2026Market cap $53M

What Ploutos Investor adds for Anavex Life Sciences

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 17 fiscal years, from FY2009
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Notes on these figures

  • The share price has fallen 80% since Aug 28, 2026, when the 10-Q these figures come from was filed ($2.99 then, $0.59 on Nov 20, 2026). The figures date from before that move.10-Q
  • The latest annual figures the company filed are for 2025, more than a year ago. Newer ones may be late.

What comes next, and what happened

Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.

Next results

10 days agoAround Nov 12, 2026 · for Q4 2026

last Aug 25, 2026next Nov 12, 2026

An estimate from when it has reported before, and the timing has varied a little. The company announces the date itself.

Its SEC filings

What it has filed lately, newest first, linked to the document itself.

Nov 25, 2025 latest annualAug 28, 2026 latest quarterly
  • Nov 3, 2026Officer or director change
    Form8-K
  • Nov 2, 2026Officer or director change, other material events
    Form8-K
  • Oct 20, 2026Other material events
    Form8-K
  • Oct 15, 2026Other material events
    Form8-K
  • Sep 28, 2026Change in control, shareholder vote
    Form8-K
  • Sep 21, 2026Filing
    FormDFAN14A
  • Sep 18, 2026Filing
    FormDFAN14A
  • Sep 17, 2026Filing
    FormDFAN14A
  • Sep 15, 2026Additional annual meeting material
    FormDEFA14A
  • Sep 15, 2026Filing
    FormDFAN14A
  • Sep 14, 2026Additional annual meeting material
    FormDEFA14A
  • Sep 10, 2026Filing
    FormDFAN14A
  • Sep 10, 2026Filing
    FormDFAN14A
  • Sep 9, 2026Filing
    FormDFAN14A
  • Sep 9, 2026Other material events
    Form8-K
  • Sep 8, 2026Additional annual meeting material
    FormDEFA14A
  • Sep 4, 2026Additional annual meeting material
    FormDEFA14A
  • Sep 4, 2026Filing
    FormDFAN14A
  • Sep 3, 2026Filing
    FormDFAN14A
  • Sep 2, 2026Other material events
    Form8-K
  • Sep 2, 2026Filing
    FormDFAN14A
  • Sep 1, 2026Additional annual meeting material
    FormDEFA14A
  • Aug 31, 2026Additional annual meeting material
    FormDEFA14A
  • Aug 28, 2026Quarterly reportfor the period to Jun 30, 2026
    Form10-Q
  • Aug 28, 2026Quarterly reportfor the period to Mar 31, 2026
    Form10-Q

From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Jan 13, 2005.

The full analysis

What do Anavex Life Sciences's filings show?

The filings are where every one of Anavex Life Sciences's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

All filings on EDGAR

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.